SCHEMBL2632669

SCHEMBL2632669

CCC(=O)c1cccnc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.61
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
BLM P54132 1/20 0.41
AGER Q15109 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MYC P01106 1/20 0.41
NAPRT Q6XQN6 2/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231066 0.83 P2RX7 (0.59) P2RX7CTNNB1WNT3AKDM4ETDP1
SCHEMBL4970018 0.83 P2RX7 (0.59) P2RX7CTNNB1WNT3AKDM4ETDP1
SCHEMBL6077799 0.83 P2RX7 (0.64) P2RX7CTNNB1WNT3AKDM4ETDP1
Hydrochloric Acid SCHEMBL7996665 0.81 P2RX7 (0.57) P2RX7CTNNB1WNT3AKDM4ETDP1
SCHEMBL11808999 0.81 P2RX7 (0.62) P2RX7CTNNB1WNT3AKDM4ETDP1
Bromide SCHEMBL15753399 0.81 P2RX7 (0.57) P2RX7CTNNB1WNT3AKDM4ETDP1
SCHEMBL13623669 0.81 PDK2 (0.44) P2RX7CTNNB1WNT3AKDM4ETDP1
SCHEMBL13545133 0.81 P2RX7 (0.43) P2RX7CTNNB1WNT3AKDM4ETDP1
SCHEMBL13623626 0.80 L3MBTL1 (0.55) TDP1ALDH1A1HPGDL3MBTL1TSHR
SCHEMBL11621763 0.80 P2RX7 (0.56) P2RX7CTNNB1WNT3AKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104284899-A Tricyclic compounds and methods of use therefor HOFFMANN LA ROCHE 2015-01-14 CN disclosed
CN-103797000-A Amidine compound or salt thereof TAISHO PHARMACEUTICAL CO LTD 2014-05-14 CN disclosed
US-8362020-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
US-7589204-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 US disclosed
US-20090187021-A1 INDANE COMPOUNDS AS CCR5 ANTAGONISTS YOUNGMAN MICHAEL 2009-07-23 US disclosed
US-7531661-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-05-12 US disclosed
US-20090053172-A1 HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS AQUINO CHRISTOPHER JOSEPH 2009-02-26 US disclosed
US-7271172-B2 Pyrrolidine and azetidine compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090053172-A1 HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS CCR5, CXCR3, CCR1 P2RX7 756/4885CTNNB1 3987/4885WNT3A 3353/4885
US-20090187021-A1 INDANE COMPOUNDS AS CCR5 ANTAGONISTS CCR5, CCL5, IDO1 P2RX7 1315/4885CTNNB1 3835/4885WNT3A 3244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.